Consensus LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Real-time Estimate Cboe BZX Other stock markets 14:54:28 2024-04-29 EDT			5-day change	1st Jan Change
6.255 ^USD	+0.89%		+6.56%	-20.11%

03-12	LifeStance Health Appoints Teresa DeLuca to Its Board of Directors	CI
03-06	Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating	MT

Evolution of the average Target Price on LifeStance Health Group, Inc.

Price target over the last 5 years

History of analyst recommendation changes

23a4f98c522bb6e0.D83ly_g8MwrM5n65klLXGoyuKpY2j6Ad87RpNgaAx0w.O6ippchKVD6GqRP8oSeycb_LGuV55-EorOEQBDXUrhtBpre4ym5VZ56KSg~388ff794abca0484d96ceaddeac40f38

Analyst Recommendations on LifeStance Health Group, Inc.

Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating	03-06	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Neutral Rating	03-04	MT
UBS Adjusts LifeStance Health Group Price Target to $9 From $7, Maintains Neutral Rating	02-29	MT
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating	02-29	MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $8 From $9, Maintains Neutral Rating	11-22	MT
JPMorgan Adjusts LifeStance Health Group's Price Target to $8 From $10, Maintains Neutral Rating	11-17	MT
UBS Cuts LifeStance Health Group's Price Target to $7 From $10, Keeps Neutral Rating	11-09	MT
Goldman Sachs Adjusts LifeStance Health Group's Price Target to $9 From $8, Keeps Neutral Rating	23-05-19	MT
UBS Adjusts LifeStance Health Price Target to $10 From $7, Maintains Neutral Rating	23-05-12	MT
Morgan Stanley Adjusts Price Target on LifeStance Health to $10 From $8, Maintains Overweight Rating	23-05-11	MT
UBS Adjusts Price Target on LifeStance Health to $7 From $6.50, Maintains Neutral Rating	23-03-09	MT
Morgan Stanley Upgrades LifeStance Health Group to Overweight From Equalweight With $8 Price Target	23-01-06	MT
Goldman Sachs Trims Price Target on LifeStance Health Group to $8 From $9, Maintains Neutral Rating	22-11-15	MT
Cowen Trims Price Target on LifeStance Health Group to $8 From $10, Maintains Outperform Rating	22-11-14	MT
UBS Adjusts LifeStance Health Group Price Target to $6.50 From $7, Maintains Neutral Rating	22-11-09	MT
Jefferies Assumes LifeStance Health at Buy Rating With $7.25 Price Target	22-11-07	MT
Cowen Adjusts Price Target on LifeStance Health Group to $10 From $11, Keeps Outperform Rating	22-08-22	MT
Jefferies Lowers Price Target for LifeStance Health Group to $10 From $15, Maintains Buy Rating	22-08-10	MT
JPMorgan Adjusts Price Target for LifeStance Health Group to $9 From $12, Maintains Neutral Rating	22-05-10	MT
Morgan Stanley Adjusts LifeStance Health Group's Price Target to $8 from $10, Keeps Equalweight Rating	22-05-10	MT
UBS Adjusts LifeStance Health Group Price Target to $7 From $10, Maintains Neutral Rating	22-05-10	MT
Goldman Sachs Adjusts LifeStance Health Group Price Target to $10 From $15, Maintains Neutral Rating	22-03-21	MT
UBS Downgrades LifeStance Health Group to Neutral From Buy, Adjusts Price Target to $10 From $19	22-03-17	MT
Morgan Stanley Adjusts Price Target on LifeStance Health to $10 From $15, Maintains Equalweight Rating	21-12-17	MT
UBS Cuts Price Target on LifeStance Health Group to $19 From $21; Buy Rating Kept	21-11-09	MT